A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US

St Charles M, Minshall ME, Pandya BJ, Baran RW, Tunis SL

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

Indexing Status
Subject indexing assigned by CRD

MeSH
Americas; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Markov Chains; Metformin; Quality-Adjusted Life Years; Thiazoles; Thiazolidinediones

AccessionNumber
22009102487

Date bibliographic record published
27/01/2010